Evidence map›Paper›PMID 32603545›Full record

ArticleJournal of diabetes investigation2021

Case of autoimmune polyendocrine syndrome type 3 complicated with anti-N-methyl-D-aspartic acid-receptor encephalitis.

Akira Kurozumi, Yosuke Okada, Kosuke Nishio, Yoshiya Tanaka

Open access · goldAbstract readCase Reports
In one paragraph

Article in Journal of diabetes investigation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 54% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Akira KurozumiFirst Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.ORCID https://orcid.org/0000-0003-1768-3752
Yosuke OkadaFirst Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
Kosuke NishioFirst Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
Yoshiya TanakaFirst Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
University of Occupational and Environmental Health Japan · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Anti-N-methyl-D-aspartate receptor (NMDA-R) encephalitis is an autoimmune disorder in which autoantibodies in the limbic system bind to GluN1 subunits of NMDA-Rs in the brain. We report a rare case of autoimmune polyendocrine syndrome type 3 complicated by anti-NMDA-R encephalitis. After hospitalization for type 1 diabetes, the 39-year-old patient developed various schizophreniform symptoms and seizures after cold-like symptoms. These findings are consistent with the diagnosis of anti-NMDA-R encephalitis. Immune-related encephalitis was suspected at the early phase of the disease, and cerebrospinal fluid was positive for anti-NMDA-R antibody. Early steroid pulse therapy was initiated during the disease course. The condition improved gradually to full recovery. Early detection and treatment of anti-NMDA-R encephalitis should enhance a positive outcome, considering that besides thyroid diseases and type 1 diabetes, various autoimmune diseases are associated with autoimmune polyendocrine syndrome type 3.

Indexed as

AdultAnti-N-Methyl-D-Aspartate Receptor EncephalitisAutoantibodiesHumansMalePolyendocrinopathies, AutoimmunePrognosisAutoantibodiesAnti-N-methyl-D-aspartic acid-receptor encephalitisAutoimmune polyglandular syndrome type 3Type 1 diabetes

Identifiers

PMID32603545
PMCPMC7858116
OpenAlexW3038693202

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.